Clinical Trial Update: Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

View source ↗

Summary

A completed clinical trial comparing Iodine-131 tositumomab with Yttrium-90 ibritumomab tiuxetan for treating non-Hodgkin's lymphoma; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Iodine-131-tositumomab (Iodine-131-tositumomab)
• Yttrium-90 ibritumomab tiuxetan (yttrium-90 ibritumomab tiuxetan)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Lymphoma | Status: COMPLETED | Results posted: 2018-08-27